Figure S9 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer

The levels of ctDNA of 15 HGS-EOC patients are shown in relation to the patient's clinical history. The TF% in cfDNA is reported for each plasma sample (purple line) withdrawn against the CA-125 levels (green line). Red bars refer to the tumor volume calculated from TC analysis as described in Supplementary methods (). * indicates patients for whom TC scan is not available at time of diagnosis and/or at recurrence. Figures S11 and S12 specifically show cases where the TF% in cfDNA does not anticipate tumor progression.